Skip to main content
BMRN
NASDAQ Life Sciences

Stockholders Approve 7.65 Million Share Increase for Equity Incentive Plan

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Neutral
Importance info
7
Price
$56.47
Mkt Cap
$10.915B
52W Low
$49.259
52W High
$66.275
52W Position info
15% above low
Off High info
15% below high
Rel. Volume info
1.0× avg
Market data snapshot near publication time

BMRN is trading near its 52-week low of $49.259 (15% above the low).

Summary

BioMarin stockholders approved an increase of 7.65 million shares for the company's equity incentive plan, enabling future equity awards but also leading to potential dilution.


Key Events · Corporate Governance and Compliance · BMRN

  • Equity Plan Share Increase Approved

    Stockholders approved an amendment to the 2017 Equity Incentive Plan, increasing the number of shares reserved for issuance by 7,650,000. If all these authorized shares were issued, dilution would be approximately 3.96% based on current outstanding shares.

  • Annual Meeting Results

    All ten director nominees were elected, KPMG LLP was ratified as the independent registered public accounting firm, and the advisory vote on named executive officer compensation was approved.


Analysis · BMRN · Life Sciences

BioMarin's stockholders approved an amendment to its 2017 Equity Incentive Plan, increasing the shares reserved for issuance by 7.65 million. This approval, following the proposal in the April 21, 2026 proxy statement, allows the company to issue additional equity awards, which will result in future dilution for existing shareholders. This potential dilution of nearly 4% is notable, especially given the company's recent acquisition and associated increase in operating expenses.

How filings like this one have moved

In the 30 days to Sep 10, 2026, 30.2% of the 2009 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.11%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, BMRN was trading at $56.47 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $10.9B. The 52-week trading range was $49.26 to $66.28. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

BMRN - Latest Insights

BMRN
Aug 31, 2026, 6:01 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $67.95
Real-time Price: $64.41 info
Change: -$3.54 (-5%) info
Market Cap: $12.468B info
BMRN
Aug 31, 2026, 2:00 AM EDT
Source: PR Newswire
Importance Score:
8
Price at Filing: $64.67
Real-time Price: $64.41 info
Change: -$0.255 (-0.39%) info
Market Cap: $12.468B info
BMRN
Aug 18, 2026, 8:39 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $67.06
Real-time Price: $64.41 info
Change: -$2.65 (-4%) info
Market Cap: $12.468B info
BMRN
Aug 18, 2026, 8:30 AM EDT
Source: Dow Jones Newswires
Importance Score:
9
Price at Filing: $67.06
Real-time Price: $64.41 info
Change: -$2.65 (-4%) info
Market Cap: $12.468B info
BMRN
Aug 06, 2026, 4:06 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $63.91
Real-time Price: $64.41 info
Change: +$0.500 (+0.78%) info
Market Cap: $12.468B info